Technical analysis of None (CGTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist.
Price Performance
| 1 month | +4.90% |
| 3 months | -28.97% |
| Year-to-date | -23.70% |
| 1 year | -29.93% |
| 3 years | -18.25% |
52-Week Range
| 52-week High | $2.26 |
| 52-week Low | $0.55 |
| Avg Volume (90d) | 1.1M |
Technical Indicators
| SMA 50 | $1.00 |
| SMA 200 | $1.18 |
| Beta | 1.40 |
| 30-day Volatility (annualised) | 54.9% |
| Price vs SMA 50 | +2.7% |
| Price vs SMA 200 | -12.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.79 | |
| 2025-11 | $1.74 | -2.8% |
| 2025-12 | $1.35 | -22.4% |
| 2026-01 | $1.09 | -19.3% |
| 2026-02 | $1.09 | +0.0% |
| 2026-03 | $0.76 | -30.3% |
| 2026-04 | $1.26 | +65.9% |
| 2026-05 | $1.18 | -6.3% |
| 2026-06 | $1.15 | -2.5% |
| 2026-07 | $0.89 | -22.6% |
| 2026-08 | $1.03 | +15.8% |
| 2026-09 | $1.03 | +0.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.02 |
| Market Cap | $91M |
Financial Health
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.99 |